SARS-CoV-2 - Colchicine - Therapeutic Candidates

SARS-CoV-2 - Colchicine - Therapeutic Candidates


Colchicine is an anti-inflammatory drug used in rheumatology and particularly for the treatment of gouty arthritis or gout. Colchicine is also used in the treatment of other pathologies such as chronic atrophic polychondritis or acute pericarditis after failure of aspirin. 
Studies have shown that SARS-CoVs activate NLRP3 inflammasomes, intracytoplasmic particles that stimulate the release of pro-inflammatory cytokines. In particular, colchicine is believed to inhibit the assembly of the NLRP3 inflammasome and thus the release of cytokines, in particular interleukin-1 beta and interleukin-6. Colchicine is believed to inhibit certain functions of the inflammasome, a component of the immune system that plays a role in triggering cytokine shock and the associated inflammatory cascade. Targeting the inflammatory response with colchicine may therefore reduce complications related to Covid-19 in adults at risk or with signs of inflammatory storm. Three studies are currently underway to investigate the effects of colchicine on Covid-19, the largest, called COLCORONA, involves 6000 patients in Canada.

Cat#
Description
Size
Price Excl. VAT
045335-5mg
 5mg 
S0320-100mg
 100mg 
T344390-100mg
 100mg 
T344390-10mg
 10mg 
T344390-1g
 1g 
T344390-250mg
 250mg 
T344390-25mg
 25mg 
A549780-100mg
 100mg 
271240-10mg
 10mg 
A549780-250mg
 250mg 
271240-25mg
 25mg 
021742-100mg
 100mg 
457447-500mg
 500mg 
271240-5mg
 5mg 
271241-100mg
 100mg 
271241-250mg
 250mg 
271241-50mg
 50mg 
021772-100mg
 100mg 
007935-50mg
 50mg 
D1770-11-25mg
 25mg 
C226-1G
 1G 
Number of results per page : 10 50 250